Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review

Systemic arterial hypertension (SAH) is a chronic disease of multifactorial origin and one of the main risk factors for major adverse cardiovascular events (MACE), which are the leading causes of morbidity and mortality worldwide. The pharmacological treatment of SAH involves five main classes of drugs, and Nebivolol (NEB) is one of those drugs, belonging to the class of third generation 131-adrenoceptors selective blockers. NEB is composed of a racemic mixture of two enantiomers: d-nebivolol, which exerts antagonist effects on 131-adrenoceptors, and l-nebivolol, a vascular 133 receptor agonist. There are several studies that report different actions of NEB, not only for the treatment of SAH, but also as an antioxidant agent or even as a protector of renal damage. The aim of this systematic review was to investigate the available evidence regarding the effects of NEB on kidney diseases, evaluating its possible renoprotective action.

Automated summary

NEB is a drug used for the treatment of systemic arterial hypertension, with potential additional effects such as antioxidant and renal protection. The aim of this study was to investigate the impact of NEB on kidney diseases.